How to buy Immix stock

Immix Biopharma Inc is a biotechnology business based in the US. Immix shares (IMMX) are listed on the NASDAQ and all prices are listed in US Dollars. Immix employs 2 staff and has a market cap (total outstanding shares value) of 0.00.

Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Immix stock price (NASDAQ: IMMX)

Use our graph to track the performance of IMMX stocks over time.

Immix shares at a glance

• Key figures

Information last updated 2022-07-02.

Latest market close	$2.60
52-week range	$1.25 - $7.90
50-day moving average more info button	$1.97
200-day moving average more info button	$2.88
Wall St. target price	N/A
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-3.93

Buy Immix shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Immix stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Immix price performance over time

Historical closes compared with the close of $2.6 from 2022-07-01

1 week (2022-06-29)	3.17%
1 month (2022-06-06)	2.36%
3 months (2022-04-06)	28.08%
6 months (2022-01-06)	-52.64%

1 year (2021-07-02)	N/A
2 years (2020-07-02)	N/A
3 years (2019-07-02)	N/A
5 years (2017-07-02)	N/A

Immix financials

Gross profit TTM	$0
Return on assets TTM	-15.46%
Return on equity TTM	-331.05%
Profit margin	0%
Book value	$1.42
Market capitalisation more info button	$36.1 million

TTM: trailing 12 months

Immix share dividends

We're not expecting Immix to pay a dividend over the next 12 months.

You may also wish to consider:

• Science Applications International (SAIC.US) (1.61% forward annual dividend yield)

Immix overview

Immix Biopharma, Inc. , a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California. .

Frequently asked questions

What percentage of Immix is owned by insiders or institutions?
Currently 62.654% of Immix shares are held by insiders and 1.618% by institutions. How many people work for Immix?
Latest data suggests 2 work at Immix. When does the fiscal year end for Immix?
Immix's fiscal year ends in December. Where is Immix based?
Immix's address is: 11400 West Olympic Boulevard, Los Angeles, CA, United States, 90064 What is Immix's ISIN number?
Immix's international securities identification number is: US45258H1068